- Home
- HLP vs ACHV Comparison
HLP vs ACHV Comparison
Compare HLP & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- ACHV
- Stock Information
- Founded
- HLP 2021
- ACHV N/A
- Country
- HLP China
- ACHV Canada
- Employees
- HLP N/A
- ACHV N/A
- Industry
- HLP Industrial Machinery/Components
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HLP Industrials
- ACHV Health Care
- Exchange
- HLP Nasdaq
- ACHV Nasdaq
- Market Cap
- HLP 96.2M
- ACHV 92.6M
- IPO Year
- HLP 2023
- ACHV N/A
- Fundamental
- Price
- HLP $1.28
- ACHV $2.78
- Analyst Decision
- HLP
- ACHV Strong Buy
- Analyst Count
- HLP 0
- ACHV 4
- Target Price
- HLP N/A
- ACHV $15.75
- AVG Volume (30 Days)
- HLP 20.0K
- ACHV 163.7K
- Earning Date
- HLP 04-08-2025
- ACHV 03-11-2025
- Dividend Yield
- HLP N/A
- ACHV N/A
- EPS Growth
- HLP N/A
- ACHV N/A
- EPS
- HLP N/A
- ACHV N/A
- Revenue
- HLP $14,045,084.00
- ACHV N/A
- Revenue This Year
- HLP N/A
- ACHV N/A
- Revenue Next Year
- HLP N/A
- ACHV N/A
- P/E Ratio
- HLP N/A
- ACHV N/A
- Revenue Growth
- HLP N/A
- ACHV N/A
- 52 Week Low
- HLP $1.00
- ACHV $2.51
- 52 Week High
- HLP $2.25
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- HLP 42.70
- ACHV 43.83
- Support Level
- HLP $1.28
- ACHV $2.70
- Resistance Level
- HLP $1.40
- ACHV $2.99
- Average True Range (ATR)
- HLP 0.04
- ACHV 0.20
- MACD
- HLP -0.01
- ACHV 0.02
- Stochastic Oscillator
- HLP 2.00
- ACHV 49.09
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.